NDA 019766 · Organon
Zocor
Simvastatin · Oral · HMG-CoA Reductase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Aug 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Dec 23, 1991
Approved uses
14
Original approval plus efficacy supplements
Registered trials
616
177 Phase 3, 25 recruiting
FAERS reports
250,259
182,048 serious, 22,333 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 28, 2025.
ZOCOR ® is indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. ZOCOR is an HMG-CoA reductase inhibitor indicated: ( 1 ) To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia.
Mechanism: Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin acid and its metabolites are inhibitors of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 16, 2003 Supplement 58 · Efficacy ReviewLabelLetter
- Oct 18, 2002 Supplement 56 · Efficacy LetterLabel
- Mar 21, 2002 Supplement 52 · Efficacy LetterReviewLabel
- Nov 7, 2000 Supplement 42 · Efficacy
- Apr 27, 2000 Supplement 40 · Efficacy LetterReviewLabel
- Nov 22, 1999 Supplement 36 · Efficacy Review
- Nov 22, 1999 Supplement 34 · Efficacy Review
- Aug 5, 1999 Supplement 32 · Efficacy Letter
- Jul 10, 1998 Supplement 28 · Efficacy LetterReview
- Jul 10, 1998 Supplement 26 · Efficacy ReviewLetter
- Mar 31, 1998 Supplement 27 · Efficacy LetterReview
- Oct 31, 1997 Supplement 21 · Efficacy
- Jun 30, 1995 Supplement 11 · Efficacy
- Dec 23, 1991 Original approval · Type 1 - New Molecular Entity Other Important Information from FDAOther
5 products under this application
- ZOCOR · SIMVASTATIN 80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- ZOCOR · SIMVASTATIN 20MG · TABLET, ORAL · Prescription · TE AB
- ZOCOR · SIMVASTATIN 5MG · TABLET, ORAL · Prescription · TE AB
- ZOCOR · SIMVASTATIN 40MG · TABLET, ORAL · Prescription · TE AB
- ZOCOR · SIMVASTATIN 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Simvastatin" as an intervention, any sponsor and status, largest first.
- Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) TrialPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT06856772 · 42,000 participants (planned) · Start Feb 28, 2025 · Primary completion Mar 28, 2028
Drug: Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin); Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) · For: Cardiovascular Diseases (CVD); Drug Effect; Atherosclerosis Cardiovascular Disease
Sites: Hellerup, Denmark
- Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVEPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00461630 · 25,673 participants · Start Jan 2007 · Primary completion Oct 2012
Drug: ER niacin/laropiprant; simvastatin and 1 more · For: Cardiovascular Disease; Peripheral Arterial Disease; Diabetes Mellitus and 1 more
Sites: Oxford, United Kingdom
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00202878 · 18,144 participants · Start Oct 17, 2005 · Primary completion Sep 18, 2014
Drug: ezetimibe/simvastatin; simvastatin and 2 more · For: Hypercholesterolemia; Myocardial Infarction
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Study of the Effectiveness of Additional Reductions in Cholesterol and HomocysteinePivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00124072 · 12,064 participants · Start Jul 1998 · Primary completion May 2008
Drug: Simvastatin 20 mg daily; Simvastatin 80 mg daily and 1 more · For: Cardiovascular Disease
Sites: Oxford, United Kingdom
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Study of Heart and Renal ProtectionPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00125593 · 9,438 participants · Start Jun 2003 · Primary completion Aug 2010
Drug: Simvastatin 20 mg; Ezetimibe 10mg and 1 more · For: Kidney Disease, Chronic
Sites: Oxford, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue13,917
- nausea13,264
- dyspnoea12,719
- diarrhoea12,137
- drug ineffective11,641
- dizziness11,247
- fall9,357
- pain9,317
- asthenia9,294
- headache9,088
- myalgia8,514
- vomiting8,304
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4,826 |
| 2005 | 5,604 |
| 2006 | 5,584 |
| 2007 | 5,313 |
| 2008 | 6,331 |
| 2009 | 8,494 |
| 2010 | 12,182 |
| 2011 | 13,612 |
| 2012 | 14,724 |
| 2013 | 13,177 |
| 2014 | 15,320 |
| 2015 | 18,481 |
| 2016 | 18,178 |
| 2017 | 15,969 |
| 2018 | 18,589 |
| 2019 | 16,748 |
| 2020 | 13,124 |
| 2021 | 9,920 |
| 2022 | 9,186 |
| 2023 | 7,747 |
| 2024 | 6,694 |
| 2025 | 6,160 |
| 2026 | 4,290 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zocor (Simvastatin)
2024 spending
$1.6M
Beneficiaries
692
2,681 claims
Per beneficiary
$2,262
$8.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $603,570 |
| 2022 | $1,850,570 |
| 2023 | $1,786,185 |
| 2024 | $1,565,299 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
· Lancet 1994 · Clinical Trial, Randomized Controlled Trial
- Simvastatin in Critically Ill Patients with Covid-19.
Hills TE, Lorenzi E, Berry LR, et al. · N Engl J Med 2023 · Multicenter Study, Randomized Controlled Trial
- Statins for multiple sclerosis.
Wang J, Xiao Y, Luo M, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
- Simvastatin as Add-On Treatment to Escitalopram in Patients With Major Depression and Obesity: A Randomized Clinical Trial.
Otte C, Chae WR, Dogan DY, et al. · JAMA Psychiatry 2025 · Randomized Controlled Trial, Multicenter Study
- Efficacy of simvastatin in bone regeneration after surgical removal of mandibular third molars.
Deepanjali M, Prasad TS, Manodh P · Oral Maxillofac Surg 2023 · Randomized Controlled Trial
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.